Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Manish A. Shah, Kei Muro et al.|Journal of Clinical Oncology|2020Cited by 1.2k
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by ImmunohistochemistryKi Y. Chung, Leonard B. Saltz, Jinru Shia et al.|Journal of Clinical Oncology|2005Cited by 1.1k
Oesophageal cancerElizabeth Smyth, David Cunningham, Jesper Lagergren et al.|Nature Reviews Disease Primers|2017Cited by 1.1k
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Jaffer A. Ajani, Florian Lordick et al.|The Lancet|2023Cited by 701
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trialManish A. Shah, Rui‐Hua Xu, Kohei Shitara et al.|Nature Medicine|2023Cited by 541